clinical trial · NCT03509545
Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide
Sarfez Pharmaceuticals, Inc.·phase1·terminated·n = 20
Body Weight ChangesCHF Patients: ER Torsemide 40 mgCHF Patients: Furosemide 40 mg
brief summary
To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.
started
Jun 30, 2021
primary completion
Jun 30, 2022
completion
Jun 30, 2022
last updated
Apr 24, 2026
detailed description
To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice-daily Furosemide on changes in body weight after two weeks of treatment. To compare the frequency and volume of urine passed in 24 hours. To compare the patients' quality of life and levels of natriuretic peptide between the two sets of patients.
official title
An Open Label,Crossover Study to Compare Once Daily Dose of 40 mg Torsemide Extended Release to Twice Daily of Furosemide on Natriuresis and Body Weight in Congestive Heart Failure (CHF) Patients Who Are on Stable Dose of Furosemide
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol